This trial is active, not recruiting.

Condition cataract
Treatment at lisa tri 839mp
Sponsor Carl Zeiss Meditec AG
Start date January 2012
End date January 2014
Trial size 120 participants
Trial identifier NCT01731743, 839 MP HEN 402-11


The purpose of the study is to evaluate the far, intermediate and near visual acuities with a trifocal IOL.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
at lisa tri 839mp

Primary Outcomes

Intermediate visual acuity
time frame: up to 3 months postoperatively

Secondary Outcomes

near and far visual acuity
time frame: 1 and 3 month postoperatively

Eligibility Criteria

Male or female participants at least 50 years old.

Inclusion Criteria: - Man or woman, over 50 years of age - Bilateral implantation of a trifocal intraocular lens - Capsular bag implantation Exclusion Criteria: - Existing ocular pathology - Surgical complications - Corneal astigmatism ≥ 1.0D

Additional Information

Description After bilateral cataract surgery, monocular and binocular uncorrected (UCVA) and best distance corrected visual acuity (BCVA) will be measured at far (4m), intermediate (80 cm) and near (40 cm) distance as well as the subjective refraction. A patient questionnaire will be used to assess the patient satisfaction and spectacle independence.
Trial information was received from ClinicalTrials.gov and was last updated in December 2013.
Information provided to ClinicalTrials.gov by Carl Zeiss Meditec AG.